Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: PrometheusTex who wrote (10025)	5/17/1999 2:03:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

Cacaito can give a better answer, but I think that everyone agrees the U.K. has done a better job of getting the public aware of the problem using things like the glass or the bottle test. So yes quicker treatment probably means lower mortality. However, the trial required patients to be graded 8 or higher on the Glasgow scale, to be eligible. If this rule was respected, it is difficult to understand what exactly is being done differently that would improve the mortality so significantly. They the reference to a Wisconsin study of 30 years of data indicating no change in mortality when data is stratified by severity. This study was also referenced in the Giroir/Scannon patent for treatment of Meningococcemia.